• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • EVENITY
    / Amgen


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre filled syringe (solution for S.C. injection)

    2

    partial basket chart

    Dosage

    Important Dosage and Administration Instructions
    Two separate syringes (and two separate subcutaneous injections) are needed to administer the total dose of 210 mg of EVENITY. Inject two 105 mg/1.17 mL prefilled syringes, one after the other.
    The first dose of EVENITY should be administered by a healthcare provider only.
    Starting from the second dose, the injection can be performed by an individual who has been properly trained by a healthcare provider only.
    Recommended Dosage
    The recommended dose of EVENITY is 210 mg administered subcutaneously in the abdomen, thigh or upper arm. Administer EVENITY once every month.
    The treatment duration for EVENITY is 12 monthly doses.
    Patients should be adequately supplemented with calcium and vitamin D during     treatment with EVENITY .
    If the EVENITY dose is missed, administer as soon as it can be rescheduled. Thereafter, EVENITY can be scheduled every month from the date of the last dose.
    Preparation and Administration Instructions: See prescribing information for full details.


    Indications

    Treatment of severe osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.


    Contra-Indications

    Hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENITY.
    A history of systemic hypersensitivity to romosozumab or to any component of the product formulation.
    Reactions have included angioedema, erythema multiforme, and urticarial.
    EVENITY is contraindicated and should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.
    Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors.
    Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur.
    If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued.


    Special Precautions

    In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITY compared to those treated with alendronate.
    Hypersensitivity Reactions
    Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticarial have occurred in EVENITY-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENITY.
    Hypocalcemia
    Hypocalcemia has occurred in patients receiving EVENITY. Correct hypocalcemia prior to initiating EVENITY.
    Monitor patients for signs and symptoms of hypocalcemia. Patients should be adequately supplemented with calcium and vitamin D while on EVENITY. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m2) or receiving dialysis are at greater risk of developing hypocalcemia.
    Monitor serum calcium and adequately supplement patients who have severe renal impairment or are receiving dialysis with calcium and vitamin D. Instruct patients with severe renal impairment, including those receiving dialysis, about the symptoms of hypocalcemia and the importance of maintaining calcium levels with adequate calcium and vitamin D supplementation.
    Osteonecrosis of the Jaw
    Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENITY. A routine oral examination should be performed by the prescriber prior to initiation of EVENITY treatment. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.
    For patients requiring invasive dental procedures, clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on benefit-risk assessment. Patients who are suspected of having or who develop ONJ while on EVENITY should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENITY should be considered based on benefit-risk assessment.


    Atypical Subtrochanteric and Diaphyseal Femoral Fractures
    Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENITY. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.
    Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs.
    During EVENITY treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patient presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of EVENITY therapy should be considered based on benefit-risk assessment.
    Immunogenicity
    As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other romosozumab products may be misleading.


    Side Effects

    Major adverse cardiac events,  Hypersensitivity, Hypocalcemia, Osteonecrosis of the Jaw, Atypical Subtrochanteric and Diaphyseal Femoral Fractures.
    See prescribing information for full details.


    Pregnancy and Lactation

    EVENITY is not indicated for use in women of reproductive potential.
    See prescribing information for full details.


    Important notes

    Storage and Handling
    The expiry date of the product is indicated on the packaging materials.
    Refrigerate EVENITY at 2°C to 8°C in the original carton to protect from light.
    Do not freeze. Do not shake.
    If removed from the refrigerator, EVENITY can be kept at room temperature up to 25°C in the original carton and must be used within 30 days. If not used within 30 days, discard EVENITY.


    Manufacturer
    Amgen Inc. USA
    Licence holder
    CLOSE